When the omicron variant coursed through the United States in 2022, it affected demographics differently—but predictably. Hispanic, Native American, Black, and Asian populations recorded higher infection rates than white people during the surge, just as they had throughout the COVID-19 outbreak. Those variations laid bare the fact that the health care industry is not immune to discrimination based on race.
That includes oncology. “We see disparities not only in incidence,” says Evelinn A. Borrayo, associate director of community outreach and engagement at the CU Cancer Center, “but, more importantly, in mortality.” And although the pattern repeats itself across the world, Colorado has unique problems. To name one: Compared with other states, Hispanic residents here suffer higher rates of lung, breast, and colorectal cancers, and though they have guesses, doctors don’t…
